文献速递精神分裂症与精神病性障碍

精神分裂症纹状体多巴胺功能的异质性:方差荟萃分析

Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance.
PubMed 文献 · Biol Psychiatry · 2019-07-25

该方差荟萃分析纳入65项分子影像研究(983例患者、968例对照),检验精神分裂症纹状体多巴胺功能的个体间变异是否超过健康人群。结果显示患者纹状体D2/3受体和DAT可用性及突触多巴胺水平的个体间变异显著大于对照,而多巴胺合成与释放能力变异无显著差异;患者总体多巴胺合成、释放能力及突触水平均值升高,但D2/3受体和DAT可用性均值无组间差异。

要点

  • 精神分裂症患者纹状体D2/3受体和DAT可用性及突触多巴胺水平的个体间变异显著大于健康对照。
  • 患者总体多巴胺合成与释放能力及突触多巴胺水平均值升高,但D2/3受体和DAT可用性均值无组间差异。
  • 这种异质性可能解释治疗反应和副作用差异,提示D2/3受体和DAT改变仅见于部分患者。

核心结论

  • 精神分裂症纹状体多巴胺功能存在显著异质性,支持多巴胺合成与释放能力升高可能是核心特征,而D2/3受体和DAT可用性及突触多巴胺水平改变可能仅见于部分患者。

研究设计与样本

  • 方差荟萃分析,纳入65项报告分子影像 measures 的研究,共983例精神分裂症患者和968例健康对照。

主要发现

  • 患者纹状体D2/3受体可用性变异比(VR)=1.26,p<.0001,显著大于对照。
  • 患者纹状体DAT可用性VR=1.31,p=.01,显著大于对照。
  • 患者突触多巴胺水平VR=1.38,p=.045,显著大于对照。
  • 多巴胺合成能力VR=1.12,p=.13,释放能力VR=1.08,p=.70,变异无显著差异。
  • 患者总体多巴胺合成能力g=0.65,p=.004;释放能力g=0.66,p=.03;突触水平g=0.78,p=.0006,均高于对照。

关键数值与推荐

  • 患者与对照D2/3受体可用性均值差异g=0.17,p=.14,无统计学意义。
  • 患者与对照DAT可用性均值差异g=-0.20,p=.28,无统计学意义。
  • 难治性患者多巴胺合成能力均值与对照无差异(p>.3)。

临床怎么用

  • 解读精神分裂症患者分子影像多巴胺指标时需考虑个体间异质性,不宜以群体均值直接推断个体。
  • D2/3受体和DAT可用性及突触多巴胺水平的改变可能仅存在于部分患者,或与治疗反应和副作用差异相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been hypothesized that dopamine function in schizophrenia exhibits heterogeneity in excess of that seen in the general population. However, no previous study has systematically tested this hypothesis. METHODS: We employed meta-analysis of variance to investigate interindividual variability of striatal dopaminergic function in patients with schizophrenia and in healthy control subjects. We included 65 studies that reported molecular imaging measures of dopamine synthesis or release capacities, dopamine D2/3 receptor (D2/3R) or dopamine transporter (DAT) availabilities, or synaptic dopamine levels in 983 patients and 968 control subjects. Variability differences were quantified using variability ratio (VR) and coefficient of variation ratio. RESULTS: Interindividual variability of striatal D2/3R (VR = 1.26, p < .0001) and DAT (VR = 1.31, p = .01) availabilities and synaptic dopamine levels (VR = 1.38, p = .045) but not dopamine synthesis (VR = 1.12, p = .13) or release (VR = 1.08, p = .70) capacities were significantly greater in patients than in control subjects. Findings were robust to variability measure. Mean dopamine synthesis (g = 0.65, p = .004) and release (g = 0.66, p = .03) capacities, as well as synaptic levels (g = 0.78, p = .0006), were greater in patients overall, but mean synthesis capacity did not differ from that of control subjects in treatment-resistant patients (p > .3). Mean D2/3R (g = 0.17, p = .14) and DAT (g = -0.20, p = .28) availabilities did not differ between groups. CONCLUSIONS: Our findings demonstrate significant heterogeneity of striatal dopamine function in schizophrenia. They suggest that while elevated dopamine synthesis and release capacities may be core features of the disorder, altered D2/3R and DAT availabilities and synaptic dopamine levels may occur only in a subgroup of patients. This heterogeneity may contribute to variation in treatment response and side effects.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brugger SP, Angelescu I, Abi-Dargham A, et al. Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. Biol Psychiatry. 2019. PMID: 31561858. doi:10.1016/j.biopsych.2019.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。